Dianthus Therapeutics, Inc.DNTH

$82.49+0.60 (+0.73%)

NASDAQHealthcare24:00 UTC

Company snapshot

Market Cap

$4B

Mid-cap

+737%

2018 — today

10-Year Price

-61%

2018 — today

52-Week Range

$17.20$95.76

Current $82.49· 83%

Dianthus Therapeutics, Inc. is a clinical-phase biotechnology firm dedicated to conceiving, developing, and providing cutting-edge monoclonal antibody treatments. These therapies are intended for individuals grappling with serious autoimmune and inflammatory conditions. The company's pipeline includes DNTH103, an investigational drug presently undergoing Phase 1 clinical assessment in patients diagnosed with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was established in 2015 and operates from its headquarters in New York, New York.

Valuation in context

P/E ratio

-749.9

N/A

Not meaningful — company is unprofitable

P/B ratio

3.3

Historically pricey

Historically pricey — last 10 years

FCF Yield

-3.3%

Near historic high

Near historic highs — last 10 years

Free · No credit card needed

Get alerted when DNTH is cheap

Set a free alert — we'll push you when P/E, yield, or other metrics cross a historical threshold.